Have Watchlists? Log in to see them here or sign up to get started.
No Items in Watchlist
There are currently no items in this Watchlist.
No Saved Watchlists
Create a list of the investments you want to track.
Something went wrong while loading Watchlist.
No Recent Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
- Open $52.93
- Day Range 50.63 - 56.95
- 52 Week Range 2.78 - 146.16
- Market Cap $2.33B
- Shares Outstanding 40.01M
- Public Float 37.31M
- Beta 1.08
- Rev. per Employee N/A
- P/E Ratio N/A
- EPS -$0.37
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 5.4M 08/13/21
- % of Float Shorted 14.48%
- Average Volume 5.88M
|5 Day|| |
|1 Month|| |
|3 Month|| |
|1 Year|| |
- Dow Jones
Cassava Sciences stock bounces 4.5% premarket, after plunging 31.4% on Wednesday
Aug. 26, 2021 at 8:44 a.m. ET by Tomi Kilgore
Cassava Sciences stock price target raised to $145 from $111 at B. Riley
Aug. 3, 2021 at 7:58 a.m. ET by Tomi Kilgore
Cassave Sciences stock price target raised to $190 from $80 at Maxim Group
Jul. 7, 2021 at 8:30 a.m. ET by Tomi Kilgore
Cassava Sciences started at buy with $78 stock price target at B. Riley
Apr. 27, 2021 at 7:35 a.m. ET by Tomi Kilgore
Cassava Sciences stock price target raised to $80 from $14 at Maxim Group
Feb. 16, 2021 at 7:53 a.m. ET by Tomi Kilgore
Cassava Sciences to offer $200 mln of shares priced at $49 each vs. $50.29 at Tuesdays close
Feb. 10, 2021 at 6:32 a.m. ET by Ciara Linnane
- Other News
- Press Releases
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Find us at the office
Chappa- Adamitis street no. 38, 81811 Tripoli, Libya
Give us a ring
+69 213 130 910
Mon - Fri, 10:00-22:00